# Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

> **NCT01253161** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 29 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Carcinoid Tumors

## Interventions

- **DRUG:** Pasireotide Long Acting Release (LAR)

## Key facts

- **NCT ID:** NCT01253161
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-01
- **Primary completion:** 2021-10-06
- **Final completion:** 2023-03-02
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01253161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01253161, "Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01253161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*